Ken Stern & Associates Inc. Buys 2,070 Shares of iShares NASDAQ Biotechnology Index (IBB)

Ken Stern & Associates Inc. grew its stake in iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 197.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,120 shares of the financial services provider’s stock after purchasing an additional 2,070 shares during the period. Ken Stern & Associates Inc.’s holdings in iShares NASDAQ Biotechnology Index were worth $333,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Pinnacle Financial Partners Inc. boosted its stake in shares of iShares NASDAQ Biotechnology Index by 201.0% in the fourth quarter. Pinnacle Financial Partners Inc. now owns 3,085 shares of the financial services provider’s stock valued at $329,000 after buying an additional 2,060 shares in the last quarter. Cetera Investment Advisers boosted its stake in shares of iShares NASDAQ Biotechnology Index by 221.0% in the fourth quarter. Cetera Investment Advisers now owns 4,651 shares of the financial services provider’s stock valued at $500,000 after buying an additional 3,202 shares in the last quarter. Cetera Advisor Networks LLC boosted its stake in shares of iShares NASDAQ Biotechnology Index by 196.2% in the fourth quarter. Cetera Advisor Networks LLC now owns 53,640 shares of the financial services provider’s stock valued at $5,734,000 after buying an additional 35,528 shares in the last quarter. Cetera Advisors LLC boosted its stake in shares of iShares NASDAQ Biotechnology Index by 221.1% in the fourth quarter. Cetera Advisors LLC now owns 35,797 shares of the financial services provider’s stock valued at $3,818,000 after buying an additional 24,648 shares in the last quarter. Finally, Cheyne Capital Management UK LLP boosted its stake in shares of iShares NASDAQ Biotechnology Index by 1,152.9% in the fourth quarter. Cheyne Capital Management UK LLP now owns 21,300 shares of the financial services provider’s stock valued at $2,274,000 after buying an additional 19,600 shares in the last quarter. 27.28% of the stock is currently owned by institutional investors and hedge funds.

Shares of iShares NASDAQ Biotechnology Index (NASDAQ IBB) opened at $107.54 on Wednesday. iShares NASDAQ Biotechnology Index has a 12 month low of $94.20 and a 12 month high of $119.30.

ILLEGAL ACTIVITY NOTICE: “Ken Stern & Associates Inc. Buys 2,070 Shares of iShares NASDAQ Biotechnology Index (IBB)” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/ken-stern-associates-inc-buys-2070-shares-of-ishares-nasdaq-biotechnology-index-ibb.html.

iShares NASDAQ Biotechnology Index Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Institutional Ownership by Quarter for iShares NASDAQ Biotechnology Index (NASDAQ:IBB)

Receive News & Ratings for iShares NASDAQ Biotechnology Index Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares NASDAQ Biotechnology Index and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply